Searched for
OM PRAKASH MANCHANDA
Add Dr Lal Pathlabs, target price Rs 2,910: HDFC SecuritiesHDFC Securities has an 'add' call on Dr Lal Pathlabs with a target price of Rs 2910. The company reported a total income of Rs 621.80 crore...- JM Financial upgrades Dr Lal Pathlabs to Buy, target price Rs 3,600JM Financial recommends buying Dr. Lal Pathlabs with a target price of Rs 3,600, citing a potential 25% upside. The company's Q3 earnings s...
- Reduce Dr. Lal Pathlabs, target price Rs 1875: Yes SecuritiesReduce Dr. Lal Pathlabs at a price target of Rs 1875.
- Buy Dr. Lal Pathlabs, target price Rs 2620: JM FinancialDr. Lal Pathlabs, incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 15012.92 Crore) operating in Hospitals & A...
- Buy Dr. Lal Pathlabs, target price Rs 2820: BNP Paribas SecuritiesPromoters held 55.05 per cent stake in the company as of 30-Sep-2022, while FIIs owned 22.37 per cent, DIIs 6.27 per cent.
- Dr Lal pulls up its socks as competition mountsGurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, ...
- Dr Lal PathLabs pulls up its socks as competition mountsGurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, ...
- Stocks in the news: YES Bank, Titan, RIL, GMR Infra, Unichem Labs and ICICI BankCLSA has retained buy rating on GAIL and sell rating on ONGC.
- Trending stocks: Dr. Lal Pathlabs shares climb over 2%A total of 1,892 shares changed hands on the counter till 10:58AM (IST).
- Outlook for diagnostics industry favourable for growth: Dr Lal PathLabsThe company said it served 1.94 crore patients and processed 4.77 crore samples
- Gautam Gambhir urges BCCI to dissolve DDCA after fracas during its AGMA source said the AGM was "disrupted by supporters of general secretary Vinod Tihara after resolution 3, 4 and removal of its Ombudsman Jus...
- Buy Dr. Lal Pathlabs, target Rs 1,249: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1249.0 and a stoploss at Rs 1136 from entry point.
- Buy Dr Lal Pathlabs, target Rs 1,235: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1235.0 and a stoploss at Rs 1148 from entry point.
- Stocks in the news: NBFCs, Adani Group scrips, Manpasand Beverages, ZEEL, IndiGo and BHELCLSA has retained sell rating on Ashok Leyland with a target price of Rs 65.
- Veteran journalist Rajat Sharma now DDCA boss, beats Madan LalThe results were on the expected lines as Sharma has the backing of BJP with the IOA president Narinder Batra throwing in all his might.
- India Inc’s top executives earn 243 times more than average staffThe number of senior executives, working with the BSE 500 companies who earned more than Rs 1 crore, increased by 43 to 848 in FY17 from th...
- Buy Dr. Lal Pathlabs, target Rs 900: Edelweiss Financial ServicesBuy Dr. Lal Pathlabs at a price target of Rs 900. Time period given by analyst is a year when Dr. Lal Pathlabs price can reach defined targ...
- Normally Q2 is the highest quarter both in terms of revenue as well as volume: Om Prakash Manchanda, Whole-time Director & CEO, Dr Lal Pathlabs LtdIn an interview with ET Now, Om Prakash Manchanda, Whole-time Director & CEO, Dr Lal Pathlabs Ltd, gives his views on the company's Q2 resu...
- Dr Lal Pathlabs looking to expand; 20% CAGR likely to sustain: Om Prakash Manchanda, CEO"The market is growing at 16% to 17%. Our own growth is likely to be sustainable as we expand to newer markets and grow further — both orga...
Load More
